Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/peds.2007-1646 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modeling absorbed alpha particle dose from diffusing alpha-emitters radiation therapy in changing tissue volumes.
Med Phys
January 2025
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Diffusing alpha-emitters Radiation Therapy ("Alpha DaRT") is a promising new radiation therapy modality for treating bulky tumors. Ra-carrying sources are inserted intratumorally, producing a therapeutic alpha-dose region with a total size of a few millimeter via the diffusive motion of Ra's alpha-emitting daughters. Clinical studies of Alpha DaRT have reported 100% positive response (30%-100% shrinkage within several weeks), with post-insertion swelling in close to half of the cases.
View Article and Find Full Text PDFEfficient Phytoremediation of Methyl Red and Methylene Blue Dyes from Aqueous Solutions by .
ACS Omega
January 2025
Department of Chemistry, University at Albany - State University of New York (SUNY), 1400 Washington Avenue, Albany, New York 12222, United States.
The contamination of water with dyes stemming from the discharge of industrial waste poses significant environmental risks and health concerns. In this study, the phytoremediation potential of the wetland plant was investigated (as a function of plant biomass, pH, contact time, and initial dye concentration) for the removal of methylene blue and methyl red dyes from wastewater. The experimental adsorption capacities under the optimum conditions were found to be 1.
View Article and Find Full Text PDFDual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
NPJ Precis Oncol
January 2025
University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.
We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1).
View Article and Find Full Text PDFFavorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits.
Vaccines (Basel)
December 2024
Drug Safety Research and Development, Pfizer Research & Development, Pearl River, NY 10965, USA.
: Respiratory syncytial virus (RSV) infections usually cause mild, cold-like symptoms in most people, but are a leading infectious disease causing infant death and hospitalization and can result in increased morbidity and mortality in older adults and at-risk individuals. Pfizer has developed Abrysvo, an unadjuvanted bivalent recombinant protein subunit vaccine containing prefusion-stabilized fusion (F) proteins representing RSV A and RSV B subgroups (RSVpreF). It is the only RSV vaccine approved for both maternal immunization to protect infants and active immunization of older adults (≥60 years) and 18-59-year-old individuals with high-risk conditions for prevention of RSV disease.
View Article and Find Full Text PDFTopographic and morphometric characterization of the humerii nutrient foramina and their implications for fracture repair and healing.
Sci Rep
January 2025
School of Life Sciences and Allied Health Professions, Anatomy Division, Kamuzu University of Health Sciences, Blantyre, Malawi.
Fractures of the humerus are common on the midshaft of the bone, often causing injury to the nutrient artery. Successful fracture repair and healing requires preservation of the blood supply to the long bones which is conveyed through the nutrient foramina (NF). The topography of long bone NF varies in different populations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!